Hemorrhagic gastritis with dabigatran in a patient with renal insufficiency

Journal of Emergency Medicine

Volumn 44, Issue 2, 2013, Pages

  Fellows, Shawn E ^a   Rosini, Jamie M ^a   Curtis, James A ^b   Volz, Emilio G ^a  

^a CHRISTIANA CARE HEALTH SYSTEM   (United States)

^b The Chester County Hospital   (United States)

Author keywords

bleeding; dabigatran etexilate; direct thrombin inhibitor; renal insufficiency; reversal

Indexed keywords

ACETYLSALICYLIC ACID; CREATININE; DABIGATRAN ETEXILATE; ESOMEPRAZOLE; FRESH FROZEN PLASMA; HEMOGLOBIN; PROTHROMBIN COMPLEX; RECOMBINANT BLOOD CLOTTING FACTOR 7A;

AGED; ANEMIA; ARTICLE; BLOOD CLOTTING DISORDER; CASE REPORT; CHRONIC KIDNEY FAILURE; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DISEASE ASSOCIATION; ERYTHROCYTE CONCENTRATE; HEART ATRIUM FIBRILLATION; HEMOGLOBIN BLOOD LEVEL; HEMORRHAGIC GASTRITIS; HEMORRHOID; HIS BUNDLE ELECTROGRAM; HOSPITALIZATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; UREA NITROGEN BLOOD LEVEL;

AGED, 80 AND OVER; ANTITHROMBINS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BLOOD COMPONENT TRANSFUSION; EMERGENCY SERVICE, HOSPITAL; ENDOSCOPY, GASTROINTESTINAL; GASTRITIS; GASTROINTESTINAL HEMORRHAGE; HUMANS; MALE; PLASMA; PYRIDINES; RENAL INSUFFICIENCY, CHRONIC;

EID: 84873105205     PISSN: 07364679     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jemermed.2012.02.042     Document Type: Article

References (34)

1. P.A. Wolf, R.D. Abbott, and W.B. Kannel Atrial fibrillation as an independent risk factor for stroke: the Framingham Study Stroke 22 1991 983 988
2. th edition) Chest 133 6 Suppl 2008 546S 592S
3. F.J. Van der Meer, F.R. Rosendaal, J.P. Vanderbroucke, and E. Briët Bleeding complications in oral anticoagulant therapy. An analysis of risk factors Arch Intern Med 153 1993 1557 1562
4. J. Hirsh, J.E. Dalen, and D.R. Anderson Oral anticoagulants. Mechanism of action, clinical effectiveness, and optimal therapeutic range Chest 114 4 Suppl 1998 445S 469S
5. S. Connolly, J. Pogue, and R. Hart Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the atrial fibrillation clopidogrel trial with ibesartan for prevention of vascular events (ACTIVE W): a randomized controlled trial Lancet 367 2006 1903 1912
6. SPORTIF-III Investigators Ximelagatran versus warfarin for stroke prevention in patients with non-valvular atrial fibrillation (SPORTIF-III): randomized controlled trial Lancet 362 2003 1691 1698
7. J.N. Fiessinger, M.V. Huisman, and B.L. Davidson Ximelagatran vs low-molecular-weight heparin and warfarin for the treatment of deep vein thrombosis: a randomized trial JAMA 293 2005 681 689
8. L. Maegdefessel, J.M. Spin, J. Azuma, and P.S. Tsao New options with dabigatran etexilate in anticoagulant therapy Vasc Health Risk Manag 6 2010 339 349
9. S.J. Connolly, M.D. Ezekowitz, and S. Yusuf Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
10. Product information. Pradaxa (dabigatran) December 2010 Boehringer Ingelheim Ridgefield, CT
11. D.W. Cockcroft, and M.H. Gault Prediction of creatinine clearance from serum creatinine Nephron 16 1976 31 41
12. T.L. Lindahl, F. Baghaei, and I.F. Blixter Effects of the oral, direct thrombin inhibitor dabigatran on five common coagulation assays Thromb Haemost 105 2011 371 378
13. J. Stangier Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate Clin Pharmacokinet 47 2008 285 295
14. M. Di Nisio, S. Middeldorp, and H.R. Büller Direct thrombin inhibitors N Engl J Med 353 2005 1028 1040
15. I.P. Casserly, D.J. Kereiakes, and W.A. Gray Point-of-care ecarin clotting time versus activated clotting time in correlation with bivalirudin Thromb Res 113 2004 115 121
16. G. Nowak The ecarin clotting time, a universal method to quantify direct thrombin inhibitors Pathophysiol Haemost Thromb 33 2003 173 183
17. J. Stangier, K. Rathgen, H. Stähle, D. Gansser, and W. Roth The pharmacokinetics, pharmacodynamics and tolerability of dabigatran etexilate, a new oral direct thrombin inhibitor, in healthy male subjects Br J Clin Pharmacol 64 2007 292 303
18. J. Stangier, K. Rathgen, H. Stähle, and D. Mazur Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study Clin Pharmacokinet 49 2010 259 268
19. J. van Ryn, J. Stangier, and S. Haertter Dabigatran etexilate - a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity Thromb Haemost 103 2010 1116 1127
20. J. Stangier, H. Stähle, K. Rathgen, W. Roth, and K. Shakeri-Nejad Pharmacokinetics and pharmacodynamics of dabigatran etexilate, an oral direct thrombin inhibitor, are not affected by moderate hepatic impairment J Clin Pharmacol 48 2008 1411 1419
21. th edition) Chest 133 6 Suppl 2008 160S 198S
22. European Medicines Agency product overview for Pradaxa. Available at: http://www.emea.europa.eu/humandocs/Humans/EPAR/pradaxa/pradaxa.htm. Accessed February 5, 2011.
23. Phytonadione. DRUGDEX System. Greenwood Village, CO: Thomson Micromedex, expires 2011 Dec 31. Available at: http://www.thomsonhc.com. Accessed January 24, 2011.
24. th edition) Chest 133 6 Suppl 2008 141S 159S
25. A.S. Rowe, and R.M. Turner Coagulation factor VIIa (recombinant) for warfarin-induced intracranial hemorrhage Am J Health Syst Pharm 67 2010 361 365
26. S. Schulman, and N.R. Bijsterveld Anticoagulants and their reversal Transfus Med Rev 21 2007 37 48
27. K.A. Vavra, M.F. Lutz, and M.A. Smyth Recombinant factor VIIa to manage major bleeding from newer parenteral anticoagulants Ann Pharmacother 44 2010 718 726
28. G. Stratmann, A.M. deSilva, and E.E. Tseng Reversal of direct thrombin inhibition after cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia Anesth Analg 98 2004 1635 1639
29. G. Fernlöf, B.M. Sjöström, K.M. Lindell, and U.E. Wall Management of major bleedings during anticoagulant treatment with the oral direct thrombin inhibitor ximelagatran or warfarin Blood Coagul Fibrinolysis 20 2009 667 674
30. W. Zhou, S. Schwarting, and S. Illanes Hemostatic therapy in experimental intracerebral hemorrhage associated with the direct thrombin inhibitor dabigatran Stroke 42 2011 3594 3599
31. M. Elg, S. Carlsson, and D. Gustafsson Effect of activated prothrombin complex concentrate or recombinant factor VIIa on the bleeding time and thrombus formation during anticoagulation with a direct thrombin inhibitor Thromb Res 101 2001 145 157
32. E.S. Erenberg, P.W. Kamphuisen, and M.K. Sijpkens Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled crossover study in healthy subjects Circulation 124 2011 1573 1579
33. P. Chowdhury, A.G. Saayman, and U. Paulus Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients Br J Haematol 125 2004 69 73
34. C.A. Naranjo, U. Busto, and E.M. Sellers A method for estimating the probability of adverse drug reactions Clin Pharmacol Ther 30 1981 239 245